Key result
Immunomodulatory nucleic acid nanoparticles emerge as a potential therapeutic strategy for CNS infections.
Why the study?
Infections of the CNS including meningitis, encephalitis, and brain abscesses remain a global problem with high incidence, mortality, and severe complications despite healthcare efforts.
Nanomedicine strategies for CNS infections remain exploratory; leaves open need for clinical validation before practice change.
Despite significant healthcare efforts, infections of the central nervous system (CNS) including meningitis, encephalitis, and brain abscesses remain a global problem.The World Health Organization reports 2.5 million cases of meningitis every year worldwide [1,2].Of these cases, one in six will succumb to infection, and one in five will develop severe complications.As a result, the World Health Organization developed a road map for eliminating epidemics, reducing vaccine-preventable cases, and improving the quality of life of individuals after meningitis by 2030.Similarly, the incidence of global encephalitis remains high with 1.4 million cases in 2019 resulting in 89,000 deaths and 4.8 million disability-adjusted life years [3].While the current incidence of brain abscesses worldwide is 4 cases per million, the prevalence of this infection continues to increase with the growing population of individuals with AIDS who exhibit increased susceptibility to infection.
No takes yet. Share an insight, caveat, or question.
M. Brittany Johnson (2024) conducted a review in Central nervous system infections (meningitis, encephalitis, brain abscesses). Immunomodulatory nucleic acid nanoparticles was evaluated. Immunomodulatory nucleic acid nanoparticles are highlighted as a potential therapeutic strategy for central nervous system infections, which continue to cause significant global morbidity and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: